Nevertheless, the outcomes of a phase I clinical trial of (213)Bi-cDTPA-9.2.27 (based on the anti-CSPG4 mAb clone 9.2.27) in advanced melanoma indicated no toxicities, a 10% objective partial response rate (108). The gene discussed is CSPG4; the disease is melanoma.